Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
23 February 2027FDA action dateRoflumilast (Zoryve)PDUFA target date 23 Feb 2027 for Zoryve cream 0.05% in infant AD
31 July 2025Filing acceptedEdaravone tablets (TTYP01)NMPA accepts the marketing application for edaravone tablets (TTYP01) in acute ischemic stroke (Huadong Medicine notice 2025-07-31)
Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share prices are end-of-day closes, delayed by 24 hours.